The US Food and Drug Administration has an exhaustive process, “to evaluate new drugs before they can be sold.” Specifically, this involves the Center for Drug Evaluation and Research (CDER). The rationale is sound and for the general good: The center’s best-known job is to evaluate new drugs before they can be sold. CDER’s evaluation not only prevents quackery, but also provides doctors and patients the information they need to use medicines wisely. The center ensures that drugs, both brand-name and generic, work correctly and that their health benefits outweigh their known risks. Note the goal is neither absolute safety nor perfect efficacy. … Continue reading →

Source: Why the Sudden Hostility Toward Off-Label Medicines? – LewRockwell LewRockwell.com